![]() |
½ÃÀ庸°í¼
»óǰÄÚµå
1611204
¹Ì±¹ÀÇ ÀÏȸ¿ë ¹ÙÀÌ¿ÀÇÁ·Î¼¼½Ì ½ÃÀå ±Ô¸ð, Á¡À¯À², µ¿Ç⠺м® º¸°í¼ : Á¦Ç°º°, ¿öÅ©Ç÷ο캰, ÃÖÁ¾ ¿ëµµº°, ºÎ¹®º° ¿¹Ãø(2025-2030³â)U.S. Single-use Bioprocessing Market Size, Share & Trends Analysis Report By Product (Simple & Peripheral Elements, Apparatus & Plants), By Workflow (Upstream, Fermentation, Downstream), By End Use, And Segment Forecasts, 2025 - 2030 |
¹Ì±¹ÀÇ ÀÏȸ¿ë ¹ÙÀÌ¿ÀÇÁ·Î¼¼½Ì ½ÃÀå ±Ô¸ð´Â 2024³â 93¾ï 4,000¸¸ ´Þ·¯·Î ÃßÁ¤µÇ¸ç, 2025-2030³â±îÁö ¿¬Æò±Õ 15.04% ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ¹ÙÀÌ¿ÀÀǾàǰ¿¡ ´ëÇÑ ³ôÀº ¼ö¿ä·Î ÀÎÇØ °ø±Þ¾÷ü´Â ÀÏȸ¿ë Á¦Ç° Á¦°øÀ» ´õ¿í °·ÂÇÏ°í Æ÷°ýÀûÀ¸·Î ¸¸µé°í ÀÖ½À´Ï´Ù. ÀÏȸ¿ë Àåºñ °ø±Þ¾÷üµéÀº ÃÖÁ¾»ç¿ëÀÚµéÀÇ °è¼Ó º¯ÈÇÏ´Â ±â´ë¿¡ ºÎÀÀÇϱâ À§ÇØ ³ë·ÂÇϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ, ¹ÙÀÌ¿À¸®¾×ÅÍ ¼³°è, È¥ÇÕ ½Ã½ºÅÛ, À¯Ã¼ ¾î¼Àºí¸® ¹× ¶óÀÌ³Ê ±â¼úÀÇ »ó´çÇÑ ±â¼ú ¹ßÀüÀº ¹ÙÀÌ¿ÀÀǾàǰ °³¹ß ¹× ¹ßÀüÀ» À§ÇÑ ÀÏȸ¿ë ±â¼úÀÇ µµÀÔÀ» ÃËÁøÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.
¹Ì±¹ÀÇ ÀÏȸ¿ë ¹ÙÀÌ¿ÀÇÁ·Î¼¼½Ì »ê¾÷Àº ƯÈ÷ ¹é½Å, Ä¡·á ¹× ºÐ¼®¿¡ ´ëÇÑ ¼ö¿ä Áõ°¡·Î ÀÎÇÑ ÀÏȸ¿ë Á¦Ç°¿¡ ´ëÇÑ ¼ö¿ä Áõ°¡·Î ÀÎÇØ COVID-19 ÆÒµ¥¹ÍÀ¸·Î ÀÎÇØ ±àÁ¤ÀûÀÎ ¿µÇâÀ» ¹Þ¾Ò½À´Ï´Ù. ÀÌ·¯ÇÑ Á¦Ç°µéÀº Àü·Ê ¾ø´Â ¼¼°è ¹é½Å ¼ö¿ä¿¡ ´ëÀÀÇϱâ À§ÇØ ¹ÙÀÌ¿À Á¦¾à ±â¾÷µéÀÌ »ý»ê ±Ô¸ð¸¦ ºü¸£°Ô È®´ëÇÏ´Â µ¥ Áß¿äÇÑ ¿ªÇÒÀ» Çß½À´Ï´Ù. À̹ø ÆÒµ¥¹ÍÀº ÀǾàǰ ¹× »ý¹°ÇÐÀû Á¦Á¦ »ý»ê¿¡¼ ¹«±Õ¼º À¯Áö¿Í ¿À¿° À§Çè ÃÖ¼ÒÈÀÇ Á߿伺À» ºÎ°¢½ÃÄ×À¸¸ç, ÀÌ·¯ÇÑ ½Ã³ª¸®¿À¿¡¼ ÀÏȸ¿ë Á¦Ç°ÀÇ Á߿伺À» °Á¶Çß½À´Ï´Ù.
¶ÇÇÑ, ÀÚº» ºñ¿ëÀÇ ´ëÆøÀûÀÎ Àý°¨, ½Ã¼³ ¿î¿µ ¹× °Ç¼³ ½Ã°£ ´ÜÃà, ȯ°æÀû Áö¼Ó°¡´É¼º µî SUT »ç¿ëÀÇ ÀåÁ¡Àº ¹ÙÀÌ¿À °øÁ¤ ½ÃÀå¿¡¼ ÀÏȸ¿ë ½Ã½ºÅÛÀÇ µµÀÔÀ» ÃËÁøÇϰí ÀÖ½À´Ï´Ù. ¹ÙÀÌ¿ÀÇÁ·Î¼¼½º¿¡¼ °ü·ù ¹× ¿¬¼Ó ¼¼Æ÷¹è¾çÀ̶ó´Â ÇöÀç »ê¾÷ Æ®·»µå´Â ÀÏȸ¿ë ÀåºñÀÇ »ç¿ëÀ» Å©°Ô °¡´ÉÇÏ°Ô Çϰí ÀÖ½À´Ï´Ù. ÀÏȸ¿ë ±â¼úÀº À̵¿¼º Çâ»ó, »ùÇøµ ¿ëÀ̼º, »ý»ê¼º Çâ»ó, ºü¸¥ Á¦Ç° ±³Ã¼ µîÀ» ÅëÇØ ¹ÙÀÌ¿À Á¦¾à »ê¾÷¿¡¼ ÀÏȸ¿ë ±â¼úÀÇ µµÀÔÀ» ´õ¿í ÃËÁøÇϰí ÀÖ½À´Ï´Ù. ¾Æ·¡ ±×¸²Àº ¹ÙÀÌ¿ÀÀǾàǰ Á¦Á¶¿¡¼ ÀÏȸ¿ë ÀåºñÀÇ »ç¿ë ÇöȲÀ» º¸¿©ÁÝ´Ï´Ù.
¶ÇÇÑ, ´Ù¿î½ºÆ®¸² Å©·Î¸¶Åä±×·¡ÇÇ¿ë ¸âºê·¹ÀÎ ÈíÂø±â ¹× Ä÷³Àº ó¸® ½Ã°£À» ´ÜÃàÇÏ°í ´õ ºü¸¥ Á¦Ç° Ãâ·ÂÀ» Á¦°øÇϸç, ÇöÀç ¼öÁö¸¦ ´ëüÇÏ´Â ÀÏȸ¿ë ½Ã½ºÅÛÀÔ´Ï´Ù. ¿¹¸¦ µé¾î, ÀǾàǰ ÃæÀü ÀÛ¾÷Àº ÀÏȸ¿ë ½Ã½ºÅÛ¿¡¼ ¼öÇà ÇÒ ¼ö ÀÖ½À´Ï´Ù. ¿¹¸¦ µé¾î, 2023³â 8¿ù Trelleborg Healthcare and MedicalÀº ÷´Ü Ä¡·á¹ý °³¹ßÀ» ÃËÁøÇϱâ À§ÇØ À¯Ã¼ °æ·Î ÀÏȸ¿ë ÀåÄ¡¸¦ À§ÇÑ Ã·´Ü Á¦Ç° ¹× ¼ºñ½º Á¦Ç°±ºÀÎ BioPharmaPro Á¦Ç°±ºÀ» Ãâ½ÃÇÏ¿´½À´Ï´Ù. ¸¶Âù°¡Áö·Î 2021³â 2¿ù, Cytiva´Â ij³ª´ÙÀÇ ¹«±Õ ÃæÀü Çõ½Å ±â¾÷ÀÎ Varnx Pharmasystems¸¦ ÀμöÇÏ¿© ÀǾàǰ ÃæÀü¿ë ÀÏȸ¿ë À¯Ã¼ °æ·Î¸¦ µµÀÔÇß½À´Ï´Ù. ÀÏȸ¿ë Æ®·»µåÀÇ ¼ºÀåÀ¸·Î ÀÎÇØ ÃæÀü ¹× ¹«±Õ ÀÛ¾÷¿ë ÀÏȸ¿ë ¿öÅ©½ºÅ×À̼ÇÀº ÀÌ ½ÃÀå¿¡ ÁøÀÔÇÏ´Â ±â¾÷µé¿¡°Ô Å« ±âȸ¸¦ Á¦°øÇÒ °ÍÀ¸·Î º¸ÀÔ´Ï´Ù.
¹ÙÀÌ¿ÀÀǾàǰ¿¡ ´ëÇÑ Áö¼ÓÀûÀÎ ¼ö¿ä¿¡ µû¶ó CMOµéÀº ÀÌ·¯ÇÑ ÀÏȸ¿ë ½Ã½ºÅÛÀ» äÅÃÇÏ¿© Á¦Ç° Æ÷Æ®Æú¸®¿À¸¦ °íµµ·Î ¿ªµ¿ÀûÀÌ°í ºó¹øÇÏ°Ô º¯°æÇϰí ÀÖÀ¸¸ç, »ç¿ë ÆíÀǼº, À¯¿¬¼º, ¿¡³ÊÁö ¹× ÀÚº» ºñ¿ë Àý°¨ ±â´É, Á¦Ç° ±³Ã¼ ÅϾî¶ó¿îµå ŸÀÓ ´ÜÃà µîÀÌ CMOµéÀÌ ÀÌ ±â¼úÀ» äÅÃÇÏ´Â ÁÖ¿ä ¿äÀÎÀ¸·Î ²ÅÈü´Ï´Ù. Á¦Ç° ÀüȯÀÇ ºü¸¥ ó¸® ½Ã°£ µîÀ» ²ÅÀ» ¼ö ÀÖ½À´Ï´Ù. À§ÀÇ ÀåÁ¡°ú ¼º´É È¿À²¼º°ú °°Àº ÇÁ·Î¼¼½º ÀÌÁ¡À» ÅëÇØ SUS´Â CMO°¡ Á¦Ç° Ä·ÆäÀÎ °£ ºü¸¥ ÀüȯÀ» °¡´ÉÇÏ°Ô Çϰí, SUS¸¦ äÅÃÇÔÀ¸·Î½á CMO´Â ´ÙǰÁ¾ »ý»ê ¼³ºñ¸¦ ±¸ÃàÇÏ°í »ó¿ë Á¦Ç°ÀÇ ºü¸¥ ½ÃÀå ħÅõ¸¦ À§ÇØ Çâ»óµÈ ¼ºñ½º¸¦ Á¦°øÇϰí ÀÖ½À´Ï´Ù. ¿¹¸¦ µé¾î, 2024³â 10¿ù ·ÐÀÚ´Â ·Î½´ÀÇ ¹ÙÄ«ºô¿¡ À§Ä¡ÇÑ Á¦³×ÅØÀÇ ½Ã¼³À» 12¾ï ´Þ·¯¿¡ ÀμöÇß½À´Ï´Ù. ÀÌ Àü·«Àû ¿òÁ÷ÀÓÀº Æ÷À¯·ù Ä¡·á¿¡ ´ëÇÑ ¼ö¿ä Áõ°¡¿¡ ´ëÀÀÇÒ ¼ö ÀÖµµ·Ï ´ë±Ô¸ð »ý¹°ÇÐÀû Á¦Á¦ »ý»ê´É·ÂÀ» Å©°Ô È®´ëÇÒ ¼ö ÀÖ°Ô µÇ¾ú½À´Ï´Ù.
The U.S. single-use bioprocessing market size was estimated at USD 9.34 billion in 2024 and is projected to grow at a CAGR of 15.04% from 2025 to 2030. Due to the high demand for biopharmaceuticals, suppliers have made their disposable product offerings more robust and inclusive. Single-use equipment suppliers are trying to fulfill end users' growing and ever-changing expectations. Furthermore, significant technological advancements in bioreactor designs, mixing systems, fluid assemblies, and liner technologies are anticipated to drive the implementation of single-use technology for biopharmaceutical developments & advancements.
The U.S. single-use bioprocessing industry experienced a positive impact from the COVID-19 pandemic, particularly due to the increased demand for single-use products driven by the heightened need for vaccines, treatments, and assays. These products played an important role in facilitating the rapid scaling up of production by biopharmaceutical companies to meet the unprecedented global demand for vaccines. The pandemic underscored the importance of maintaining sterility and minimizing contamination risks in pharmaceutical and biologics production, highlighting the significance of single-use products in such scenarios.
Furthermore, the benefits of using SUT, such as significant cost reduction in capital, decreased time in operation & construction of a facility, and environmental sustainability, have supported the implementation of single-use systems in the bioprocessing market. The current industry trend of perfusion and continuous cell culture in bioprocessing has greatly enabled the use of single-use equipment. Single-use technologies offer enhanced mobility, ease of sampling, higher productivity, and faster product changeovers, further boosting their implementation in the biopharmaceutical industry. The following figure represents the usage of single-use disposables in biopharmaceutical manufacturing.
In addition, membrane adsorbers and columns for downstream chromatography have provided faster product output with decreased processing time and are now the single-use alternative to resins. For instance, drug product-filling operations can be carried out in single-use systems. For instance, in August 2023, Trelleborg Healthcare and Medical launched the BioPharmaPro family of advanced products and services for fluid path single-use equipment to boost the development of advanced therapies. Similarly, in February 2021, Cytiva acquired Varnx Pharmasystems, a Canadian aseptic filling innovator, and brought single-use flow paths for drug product filling. Due to the growth in single-use trends, the single-use workstation for filling and sterile operations will pose a great opportunity for the players in this market.
With the continued demand for biopharmaceuticals, CMOs have adopted these single-use systems for highly dynamic and frequent changes in product portfolios. Some of the major factors for the adoption of this technology by the CMOs are ease of use, flexibility, energy & capital cost reduction features, and decreased turnaround time for product changeover. Due to the benefits above and process advantages like performance efficiency, SUS has allowed CMOs to transition between product campaigns quickly. The adoption of SUS has resulted in CMOs building multiproduct facilities and providing enhanced services for faster market penetration of commercial products. For instance, in October 2024, Lonza acquired Roche's Genentech facility in Vacaville for USD 1.2 billion. This strategic move significantly expanded its large-scale biological manufacturing capacity, catering to the growing demand for mammalian therapies.
U.S. Single-use Bioprocessing Market Report Segmentation
This report forecasts revenue growth and provides an analysis of the latest trends in each of the sub-segments from 2018 to 2030. For this report, Grand View Research has segmented the U.S. Single-use bioprocessing market report based on product, workflow, and end use.